" OPKO Health, Inc. (OPK), a multinational biopharmaceutical and diagnostics company that is developing a novel long-acting human growth hormone product (hGH-CTP) for the treatment of growth hormone deficiency (GHD), today announced it will hold a conference call and webcast on Tuesday, June 24, 2014 at 8:30 a.m. EDT (7:30 a.m. CDT).
During the call, OPKO Biologics management will discuss data from the company's advanced phase 2 trial of hGH-CTP in growth hormone deficient pediatric subjects. The pharmacokinetic and pharmacodynamics portion of the results will also be presented at a poster presentation on the prior Monday afternoon from 2:00 p.m. to 4:00 p.m. EDT (1:00 p.m. to 3:00 p.m. CDT) during the International Congress of Endocrinology and Endocrine Society's Annual Meeting and Expo at the McCormick Place West in Chicago, IL."
Not quite right either. It does not highlight the positive, pps moving trial result that will be presented.
It should say: The preliminary efficacy that had been observed in pre-treated and relapsed RCC patients will be discussed in more detail. Efficacy is the word. Or "Asonep delays disease progression in RCC patients who have relapsed from prior treatments". Or "Asonep improves progression free survival of RCC patients who have relapsed from prior treatments, compared to historical numbers.
Notice this six month data of a 12 month trial. Lpath is not at the end of cohort 1, if they were they probably would have included the data at ASCO.
"The data to be discussed during the call will include six month height velocity and safety data from the company's phase 2 trial, which is a one year dose finding study administering hGH-CTP to growth hormone deficient children once a week using daily hGH as a comparator arm. "